Predicting consequences of new hepatitis B vaccine recs
New research projects that the Trump administration's policy change on hepatitis B vaccination will lead to more infected babies and increased healthcare costs. The CDC's Advisory Committee on Immunization Practices, filled with political appointees, made the recommendation despite a lack of evidence on adverse effects.
The Trump administration adopted a new policy late last year recommending a delay in hepatitis B vaccination for most babies, overturning a 30-year policy that had contributed to a decline in cases. New research published yesterday projects that this change will lead to more infected babies, more children with chronic infections, and millions of extra dollars spent on healthcare costs. The CDC's Advisory Committee on Immunization Practices, which was re-filled with political appointees last year, made the recommendation without reviewing the typical research. There's no evidence of adverse effects from the previous policy. The change is expected to have significant consequences for public health.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.